Invention Grant
- Patent Title: Azelaic acid esters in the treatment of insulin resistance
-
Application No.: US16267338Application Date: 2019-02-04
-
Publication No.: US11026912B2Publication Date: 2021-06-08
- Inventor: Robert T. Streeper , Elzbieta Izbicka
- Applicant: NEW FRONTIER LABS, LLC
- Applicant Address: US TX San Antonio
- Assignee: NEW FRONTIER LABS, LLC
- Current Assignee: NEW FRONTIER LABS, LLC
- Current Assignee Address: US TX San Antonio
- Agency: Pillsbury Winthrop Shaw Pittman, LLP
- Main IPC: A61K31/23
- IPC: A61K31/23 ; A61K9/00 ; A61K31/337 ; A61K31/573 ; A61K45/06 ; A61K31/225
Abstract:
A method of treating insulin resistance includes administering to a subject a pharmaceutical composition comprising diethyl azelate. For example, a method of treating insulin resistance includes orally administering to a subject a pharmaceutical composition that includes diethyl azelate at a dosage range from about 0.1 mg/kg/day to about 10 mg/kg/day.
Public/Granted literature
- US20190167627A1 AZELAIC ACID ESTERS IN THE TREATMENT OF INSULIN RESISTANCE Public/Granted day:2019-06-06
Information query
